Scandion Oncology’s management and Board of Directors have exercised their Scandion Oncology A/S series TO 1 warrants
Scandion Oncology announces that its management team and its Board of Directors have all exercised their Scandion Oncology A/S series TO 1 warrants.The subscription period for the series TO 1 warrants issued as part of Scandion Oncology A/S (”Scandion Oncology”) rights issue conducted in June 2019 will continue until October 1, 2020. The last day for trading with the series TO 1 warrants is September 29, 2020. Holders of the series TO 1 warrants are entitled to subscribe for one new share for each warrant at a price of SEK 5.20 per share. Please note that warrants that have not been